Surmodics Shares Soar 50% on PROWL Registry Data and Q3 Earnings Momentum
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Surmodics Inc (NASDAQ: SRDX) is a provider of surface modification technologies and chemical components for the medical device and in vitro diagnostics (IVD) markets. Founded in 1979 and headquartered in Eden Prairie, Minnesota, the company develops hydrophilic, hemocompatible, and drug-delivery coatings for intravascular devices, offers contract development and manufacturing services, and supplies performance coatings and reagents for immunoassay tests and microarrays. The company’s Korean name is 서모딕스.
Corporate Structure
Surmodics is publicly traded and, according to LinkedIn data as of 2025, employs approximately 201–500 staff. Approximately one in three employees holds a degree in science or engineering fields such as chemistry, biochemistry, biology, materials science, or mechanical engineering. The company maintains manufacturing facilities in the United States and Ireland and holds ISO 13485:2016 and ISO 9001:2015 certifications to uphold quality assurance across its operations.
Medical Devices by Daniel Frank
Developments and News
On November 7, 2025, Surmodics filed a Schedule 13G/A amendment with the U.S. Securities and Exchange Commission indicating that Soleus Capital Master Fund, L.P. and Soleus Capital, LLC reported zero shares owned as of September 30, 2025.
At the VIVA25 conference in Las Vegas on November 3, 2025, lead investigators presented data from the PROWL Registry pertaining to 160 patients treated with the Pounce™ Thrombectomy Platform. The data indicated that 64.4 percent of patients avoided ICU admission and 81.9 percent were discharged home following lower extremity limb ischemia treatment.
In its Form 10-Q and Form 8-K filings dated August 8, 2025, Surmodics reported second-quarter revenue trends and ongoing investments in R&D for advanced coatings and IVD reagents. The filings outlined strategic initiatives to expand its presence in peripheral vascular and in vitro diagnostic markets.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share price (2025-11-11) | $41.04 (+50.09 % day change) |
| Volume | 198,272 shares |
| Market cap (intraday) | $390.97 million |
| Revenue (TTM) | $120.8 million |
| Net income (TTM) | –$17.6 million |
| Price/Sales (TTM) | 3.16 |
| Beta (5Y Monthly) | 1.39 |
| EPS (TTM) | –1.24 |
| Analysts’ rating | BUY |
| 1-year target price range | $19 – $26 |
The 50.09 percent share price increase on November 11, 2025, coincided with the company’s third-quarter earnings release scheduled for the same day. Trading volume of 198,272 shares exceeded the three-month average of 175,154. Surmodics’s revenue base—which includes device coatings, contract manufacturing, and diagnostic reagents—supports its strategy to manage volatility across different segments.
Market Position and Industry Context
Surmodics operates within the medical equipment manufacturing industry, competing against global medtech firms and specialized diagnostic suppliers. Its core competencies include proprietary surface technologies for intravascular devices and formulations for immunoassays. Regulatory compliance with FDA requirements and ISO standards is fundamental to its product development and commercialization processes. Customers in in vitro diagnostics benefit from Surmodics’s comprehensive support from concept through scalable manufacturing.
tl;dr
Surmodics shares increased 50.09 percent to $41.04 on November 11, 2025, influenced by PROWL Registry data presented at VIVA25 on November 3 and the upcoming Q3 earnings announcement. The institutional ownership filings on November 7 confirmed zero ownership by key investors as of September 30. Future earnings commentary and related clinical studies will provide insight into the near-term outlook.